Who
Mary Lynne Hedley
Director
Company insider
Files Form 4 as: Director, Veeva Systems; Director, Centessa Pharmaceuticals; Director, Eli Lilly and; Director, Tempest Therapeutics; President & COO, Tesaro; Director, bluebird bio; Director, Receptos; Executive VP of Ops & CSO, Abraxis BioScience.
In numbers
- Trades disclosed
- 221
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $1.1M
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 15 Jul 2006
- Last trade
- 1 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 3 Sep 2026 | VEEV Veeva SystemsSoftware | SEC FORM 4 Code M | —477 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | VEEV Veeva Systemsoption or derivative · Software | SEC FORM 4 Code M | —477 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | VEEV Veeva Systemsoption or derivative · Software | SEC FORM 4 Code M | —477 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | VEEV Veeva SystemsSoftware | SEC FORM 4 Code M | —477 at $0.00 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —208,474 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —208,474 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —48,000 | filing |
| 24 Jun 2026filed 24 Jun 2026 | Centessa Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —40,000 | filing |
| 17 Jun 2026filed 22 Jun 2026 | VEEV Veeva Systemsoption or derivative · Software | SEC FORM 4 Code A | —1,906 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | VEEV Veeva Systemsoption or derivative · Software | SEC FORM 4 Code A | —1,906 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | VEEV Veeva SystemsSoftware | SEC FORM 4 Code M | —262 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | VEEV Veeva Systemsoption or derivative · Software | SEC FORM 4 Code M | —262 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | VEEV Veeva Systemsoption or derivative · Software | SEC FORM 4 Code M | —262 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | VEEV Veeva SystemsSoftware | SEC FORM 4 Code M | —262 at $0.00 | filing |
News
Veeva Systems (NYSE:VEEV) Hits New 12-Month High on Analyst UpgradeVEEV · tickerreport.com · 20 Oct 2026Barclays Forecasts Strong Price Appreciation for Veeva Systems (NYSE:VEEV) StockVEEV · dailypolitical.com · 19 Oct 2026Veeva Systems (NYSE:VEEV) SVP Jonathan Faddis Sells 5,198 Shares of Company StockVEEV · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Mary Lynne Hedley; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.